Genital Herpes - Pipeline Review, H2 2020

August 2020 | 123 pages | ID: GE1FCDDDF3AEN
Global Markets Direct

Abstracts

Genital Herpes - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H2 2020, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 5, 23 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Genital Herpes - Overview
Genital Herpes - Therapeutics Development
Genital Herpes - Therapeutics Assessment
Genital Herpes - Companies Involved in Therapeutics Development
Genital Herpes - Drug Profiles
Genital Herpes - Dormant Projects
Genital Herpes - Discontinued Products
Genital Herpes - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Genital Herpes, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Genital Herpes - Pipeline by Abivax SA, H2 2020
Genital Herpes - Pipeline by AiCuris GmbH & Co KG, H2 2020
Genital Herpes - Pipeline by Anteris Technologies Ltd, H2 2020
Genital Herpes - Pipeline by Astellas Pharma Inc, H2 2020
Genital Herpes - Pipeline by Auritec Pharmaceuticals Inc, H2 2020
Genital Herpes - Dormant Projects, H2 2020
Genital Herpes - Dormant Projects, H2 2020 (Contd..1), H2 2020
Genital Herpes - Dormant Projects, H2 2020 (Contd..2), H2 2020
Genital Herpes - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Genital Herpes, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Abivax SA
AiCuris GmbH & Co KG
Anteris Technologies Ltd
Astellas Pharma Inc
Auritec Pharmaceuticals Inc
Biomere LLC
BlueWillow Biologics Inc
Brandenburg Antiinfektiva GmbH
Johnson & Johnson
NanoViricides Inc
Profectus BioSciences Inc
Rational Vaccines Inc
Redbiotec AG
Sanofi
Shulov Innovative Science Ltd
SL VaxiGen Inc
Squarex LLC
Stabilitech Biopharma Ltd
Starpharma Holdings Ltd
Stealth Biologics LLC
Thyreos LLC
United BioPharma Inc
Vaccibody AS
Vaxart Inc
Vaxxit Srl
Vir Biotechnology Inc
Viramatix Sdn Bhd
Vironova Medical AB
X-Vax Technology Inc